|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
32,670,000 |
Market
Cap: |
29.20(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.615 - $1.06 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Harpoon Therapeutics is a clinical-stage immunotherapy company. Co.'s Tri-specific T cell Activating Construct (TriTACs) product candidates include: HPN328, which is for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217, which is for the treatment of multiple myeloma; and HPN536, which is for the treatment of ovarian and pancreatic cancers and other mesothelin- expressing solid tumors. Co.'s proprietary TriTAC product candidate is HPN601, which targets the epithelial cell adhesion molecule and is being developed for the treatment of multiple solid tumor indications.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
21,397,205 |
21,397,205 |
24,484,205 |
24,494,205 |
Total Buy Value |
$492,135,715 |
$492,135,715 |
$492,135,715 |
$502,135,715 |
Total People Bought |
1 |
1 |
3 |
3 |
Total Buy Transactions |
1 |
1 |
4 |
5 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-04-27 |
4 |
AS |
$20.99 |
$250,539 |
I/I |
(11,829) |
7,008,291 |
|
-58% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-04-21 |
4 |
AS |
$18.94 |
$170,229 |
I/I |
(8,972) |
7,020,120 |
|
-52% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-04-20 |
4 |
AS |
$18.70 |
$416,382 |
I/I |
(22,249) |
7,029,092 |
|
-49% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-04-19 |
4 |
AS |
$19.29 |
$194,059 |
I/I |
(10,056) |
7,051,341 |
|
-51% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-04-16 |
4 |
AS |
$19.82 |
$116,110 |
I/I |
(5,847) |
7,061,397 |
|
-53% |
|
Evnin Luke |
Former 10% Owner |
|
2021-04-15 |
4 |
AS |
$20.49 |
$21,555 |
I/I |
(1,052) |
3,220,844 |
|
-55% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-04-15 |
4 |
AS |
$20.49 |
$178,181 |
I/I |
(8,696) |
7,067,244 |
|
-55% |
|
Evnin Luke |
Former 10% Owner |
|
2021-04-14 |
4 |
AS |
$20.06 |
$34,714 |
I/I |
(1,671) |
3,221,896 |
|
-56% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-04-14 |
4 |
AS |
$20.06 |
$286,809 |
I/I |
(13,806) |
7,075,940 |
|
-56% |
|
Evnin Luke |
Former 10% Owner |
|
2021-04-13 |
4 |
AS |
$19.35 |
$37,806 |
I/I |
(1,943) |
3,223,567 |
|
-57% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-04-13 |
4 |
AS |
$19.35 |
$312,369 |
I/I |
(16,054) |
7,089,746 |
|
-57% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-04-12 |
4 |
AS |
$20.72 |
$433,556 |
I/I |
(20,628) |
7,105,800 |
|
-58% |
|
Evnin Luke |
10% Owner |
|
2021-04-12 |
4 |
AS |
$20.72 |
$52,460 |
I/I |
(2,496) |
3,225,510 |
|
-58% |
|
Ubs Oncology Impact Fund L.p. |
10% Owner |
|
2021-04-09 |
4 |
AS |
$23.67 |
$243,801 |
I/I |
(10,300) |
7,126,428 |
|
-59% |
|
Evnin Luke |
10% Owner |
|
2021-04-09 |
4 |
AS |
$23.67 |
$243,801 |
I/I |
(10,300) |
3,228,006 |
|
-59% |
|
Erbez Georgia |
Chief Financial Officer |
|
2021-02-17 |
4 |
OE |
$2.12 |
$53,000 |
D/D |
25,000 |
72,292 |
|
- |
|
Evnin Luke |
10% Owner |
|
2021-02-10 |
4 |
AS |
$20.00 |
$3,661,020 |
I/I |
(183,051) |
3,238,306 |
|
-31% |
|
Evnin Luke |
10% Owner |
|
2021-02-09 |
4 |
AS |
$20.25 |
$190,350 |
I/I |
(9,400) |
3,421,357 |
|
-24% |
|
Evnin Luke |
10% Owner |
|
2021-02-08 |
4 |
AS |
$20.04 |
$1,445,445 |
I/I |
(72,128) |
3,430,757 |
|
-25% |
|
Evnin Luke |
10% Owner |
|
2021-02-05 |
4 |
AS |
$20.01 |
$203,542 |
I/I |
(10,172) |
3,502,885 |
|
-23% |
|
Evnin Luke |
10% Owner |
|
2021-02-04 |
4 |
AS |
$20.37 |
$605,600 |
I/I |
(29,730) |
3,513,057 |
|
-24% |
|
Evnin Luke |
10% Owner |
|
2021-02-03 |
4 |
AS |
$20.21 |
$847,244 |
I/I |
(41,922) |
3,542,787 |
|
-24% |
|
Evnin Luke |
10% Owner |
|
2021-02-02 |
4 |
AS |
$20.13 |
$974,715 |
I/I |
(48,421) |
3,584,709 |
|
-23% |
|
Evnin Luke |
10% Owner |
|
2021-01-27 |
4 |
AS |
$20.00 |
$14,136,500 |
I/I |
(706,825) |
3,633,130 |
|
-22% |
|
Evnin Luke |
10% Owner |
|
2021-01-26 |
4 |
AS |
$21.08 |
$28,732 |
I/I |
(1,363) |
4,339,955 |
|
-26% |
|
213 Records found
|
|
Page 4 of 9 |
|
|